rss
J Clin Pathol 2003;56:914-918 doi:10.1136/jcp.56.12.914
  • Original article

Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour

  1. A Etges1,
  2. D S Pinto, Jr2,
  3. L P Kowalski3,
  4. F A Soares4,
  5. V C Araújo2
  1. 1Oral Pathology, School of Dentistry, Federal University of Pelotas/UFP, Pelotas, Rio Grande do Sol, Brazil, CEP 96015
  2. 2Oral Pathology, School of Dentistry, University of São Paulo/USP, Säo Paulo, Brazil, CEP 1509-900
  3. 3Head and Neck Surgery and Otorhinolaryngology Department, Cancer Hospital AC Camargo, São Paulo, Brazil, 01509010
  4. 4Pathology Department, Cancer Hospital A. C. Camargo, São Paulo, Brazil
  1. Correspondence to:
 Dr V C de Araújo
 Faculdade de Odontologia da Universidade de São Paulo/USP, São Paulo, Avenida Prof. Lineu de Azevedo Prestes, 2227, Cidade Universitária, São Paulo, SP, Brasil, CEP: 01509-900; vcaraujousp.br
  • Accepted 29 May 2003

Abstract

Background: Salivary duct carcinoma (SDC) is considered to be a distinct malignancy of the major salivary glands, because of its highly aggressive behaviour, and the high rate of recurrence, metastasis, and disease related death.

Aims: To investigate expression of the proteins involved in the retinoblastoma (pRb) and p53 pathways, which control cell cycle progression at the G1/S checkpoint, and also expression of the c-erbB-2 oncoprotein in SDCs.

Methods: Using a streptavidin–biotin method, five cases of SDC were evaluated immunohistochemically for the presence of cyclin D1, CDK4 (cyclin dependent kinase 4), p16 (CDK2A), pRb (retinoblastoma protein), E2F-1, p53, mdm2 (murine double minute 2), bcl-2, and the c-erbB-2 oncoprotein to determine whether there was a correlation between the expression of these proteins and patient outcome.

Results: All of the cases showed deregulation of the pRb and p53 pathways. Of the five patients analysed, only the patient with longterm survival (10 years) was not positive for c-erbB-2 expression.

Conclusions: c-erbB-2 overexpression was associated with a poor prognosis. Aggressive behaviour, recurrence, and metastatic potential do not appear to be related to cell cycle deregulation, but seem to be associated with the c-erbB-2 oncoprotein, which is involved in matrix degradation and proteolitic activity, in addition to increases in vessel permeability, endothelial cell growth, proliferation, migration, and differentiation. There was a correlation between c-erbB-2 oncoprotein expression and aggressive behaviour in SDCs.

Footnotes

    This Article

    Services

    1. Request permissions

    Responses

    1. Submit a response
    2. No responses published

    Social bookmarking

    Latest from JCP Education

    Latest from JCP Education

    Register for free content


    Free sample
    This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JCP.
    View free sample issue >>

    Free archive
    The full back archive is now available for JCP. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
    Register to access the free archive >>

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

  • Latest Pathology jobs

    Latest Pathology jobs